Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Silva lining for Tech City’s future

2 August 2013

By Stephen Caddick, University College London
In 10 Downing Street’s Rose Garden a few weeks ago, Rohan Silva, the architect of Tech City, said goodbye to his formal role in Government and, with that, an extraordinary period in the development of East London.

Read the full article